TEVA · Teva Pharmaceutical Industries Ltd
$30.81
-0.37 (-1.19%)
At close · Jul 24
Market Cap
$35.88B
Shares
1.16B
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Richard Francis | CEO | $19,168,709 |
| Evan Lippman | Executive Vice President, Business Development | $7,222,009 |
| Eli Kalif | CFO | $6,961,991 |
| Dr. Eric A. Hughes | Executive Vice President, Global R&D and Chief Medical Officer | $6,298,933 |
| Christine Fox | Chief Financial Officer | $5,895,161 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Richard Francis | CEO | $15,518,947 |
| Eli Kalif | CFO | $6,175,059 |
| Dr. Eric A. Hughes | Executive Vice President, Global R&D and Chief Medical Officer | $5,754,787 |
| Richard Daniell | Executive Vice President, European Commercial | $5,433,292 |
| Christine Fox | Chief Financial Officer | $5,218,023 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Richard Francis | CEO | $25,706,880 |
| Richard Daniell | Executive Vice President, European Commercial | $5,164,163 |
| Eli Kalif | CFO | $4,943,832 |
| Mark Sabag | Executive Vice President, International Markets Commercial | $3,729,134 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Dr. Sven Dethlefs | Executive Vice President, North America Commercial | $4,063,280 |
| Eli Kalif | CFO | $4,014,617 |
| Mark Sabag | Executive Vice President, International Markets Commercial | $3,923,933 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Dr. Sven Dethlefs | Executive Vice President, North America Commercial | $3,817,377 |
| Mark Sabag | Executive Vice President, International Markets Commercial | $3,788,741 |
| Eli Kalif | CFO | $3,544,983 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Dr. Hafrun Fridriksdottir | Executive Vice President, Global Research & Development | $4,290,333 |
| Brendan O’Grady | CEO | $4,126,283 |
| Eli Kalif | CFO | $3,723,815 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Dr. Hafrun Fridriksdottir | Executive Vice President, Global Research & Development | $4,377,725 |
| Dr. Carlo de Notaristefani | Former Executive Vice President, Global Operations | $4,318,838 |
| Michael McClellan | CFO | $4,231,243 |
| Brendan O’Grady | CEO | $3,462,290 |
| Eli Kalif | CFO | $20,555 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Dr. Carlo de Notaristefani | Former Executive Vice President, Global Operations | $7,242,520 |
| Dr. Hafrun Fridriksdottir | Executive Vice President, Global Research & Development | $5,975,031 |
| Michael McClellan | CFO | $4,946,010 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Dr. Carlo de Notaristefani | Former Executive Vice President, Global Operations | $4,462,359 |
| Dr. Hafrun Fridriksdottir | Executive Vice President, Global Research & Development | $3,708,842 |
| Michael McClellan | CFO | $1,104,173 |
Key facts
CIK
818686
CUSIP
881624209
13F (30d)
156 filings
144 filers
Visit website
Investor relations